( February 24, 2025, 2:16 PM EST) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals was wrong to reverse a Delaware federal judge’s finding of no induced infringement in a patent dispute involving a generic bioequivalent of a prescription cardiovascular drug, the maker of the bioequivalent told the U.S. Supreme Court in a petition for a writ of certiorari....